Sections View Full Chapter Figures Tables Videos Annotate Full Chapter Figures Tables Videos Supplementary Content + • 2 types: virilizing and feminizing• Virilization is due to hypersecretion of adrenal androgens, mainly dehydroepiandrosterone (DHEA), its sulfate derivative (DHEAS), and androstenedione. All of these are converted peripherally to testosterone and 5α-dihydrotestosterone • Very rarely do virilizing adrenal tumors secrete only testosterone• Estrogens are not normally synthesized by the adrenal cortex +++ Epidemiology + • These tumors are rare• 70% of virilizing adrenal tumors exhibit malignant behavior• Virilizing adrenal tumors in children are less likely to be malignant +++ Symptoms and Signs + • Virilization includes hirsutism, male pattern baldness, acne, deep voice, male musculature, irregular menses or amenorrhea, clitoromegaly, and increased libido• Rapid linear growth with advanced bone age is common in children with virilizing tumors• Feminization in men (bilateral gynecomastia, accelerated growth rate, female hair distribution, advanced bone age), or precocious puberty in women• Feminizing adrenal tumors may present with vaginal bleeding in adult women +++ Laboratory Findings + • Virilizing adrenal tumors: Elevated DHEA, DHEAS, androstenedione, and testosterone• Feminizing adrenal tumors: Elevated plasma or urine estrogens +++ Imaging Findings + • Adrenal cortical mass on CT or MRI + • Differentiating between benign and malignant virilizing adrenal tumors, even with histopathology, is very difficult• Feminizing adrenal tumors are almost always carcinomas +++ Rule Out + • Congenital adrenal hyperplasia• Ovarian tumors• Testicular feminization• Exogenous estrogen administration + • Complete history and physical exam• Plasma androgen levels; urine and plasma estrogen levels• Localization with CT or MRI + • Resection is the only successful treatment +++ Surgery +++ Indications + • All virilizing adrenal tumors should be resected• All feminizing adrenal tumors should be excised +++ Prognosis + • Worse for large virilizing tumors (> 100 g)• Guarded for feminizing adrenal tumors +++ References ++Cordera F et al: Androgen-secreting adrenal tumors. Surgery 2003;134:874. [PubMed: 14668717] ++Latronico AC et al: Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab 1997;82:1317. [PubMed: 9141510] ++Liou LS et al: Adrenocortical carcinoma in children. Review and recent innovations. Urol Clin North Am 2000;27:403. [PubMed: 10985141] ++Merk DP et al: NIH conference. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002;136:320. ++Moreno S et al: Profile and outcome of pure androgen-secreting adrenal tumors in women: experience of 21 cases. Surgery 2004;136:1192. [PubMed: 15657575] Your Access profile is currently affiliated with [InstitutionA] and is in the process of switching affiliations to [InstitutionB]. Please select how you would like to proceed. Keep the current affiliation with [InstitutionA] and continue with the Access profile sign in process Switch affiliation to [InstitutionB] and continue with the Access profile sign in process Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Error: Incorrect UserName or Password Username Error: Please enter User Name Password Error: Please enter Password Sign in Forgot Password? Forgot Username? Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free profile for additional features.